

Thermo Fisher introduces cell, gene therapy integrated packaging services

16 February 2022 | News

End-to-end solution combines cryogenic and cold chain logistics, serialization compliance and global distribution



Cell and gene therapy innovators can now leverage new integrated commercial packaging and distribution services from Thermo Fisher Scientific, designed to seamlessly transition therapies from clinic to commercial launch for patients across the US and Europe.

The Patheon Commercial Packaging Services for Cell and Gene Therapies (CGT) is an end-to-end solution combining the GMP storage, serialization, ultracold and cryogenic packaging, and global distribution that developers need to support their logistics strategies.

The cell and gene therapy market is expected to reach a commercialisation inflection point, with the FDA anticipating 10-20 new approvals per year through 2025. In launching these new therapies, cell and gene therapy developers require specific validated processes for their commercial logistics strategy from labelling to shipping.